Development of a machine learning-based model for prediction of diabetes risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

Read full text
Authors: Sijie Yang, Ruiqing Mo, Wenqiang Wang, Puxiang Zhen, Wentian Han
Cited by: 2
References: 38

Abstract

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading chronic liver disorder closely linked to diabetes mellitus (DM) and its cardiovascular and renal complications. Early identification of diabetes risk in this population is essential for timely intervention. OBJECTIVE: To develop machine learning (ML) models to predict diabetes risk in individuals with MASLD and to identify key predictive factors using a nationally representative dataset. METHODS: Data from 6310 MASLD participants (2007-2018) were analysed and classified into DM and non-DM groups. Feature selection was performed using Random Forest, Least Absolute Shrinkage and Selection Operator and Support Vector Machine Recursive Feature Elimination. Based on selected features, nine ML models were developed. Model performance was evaluated using accuracy, sensitivity, area under the curve, F1 score, Rank Score and Brier Score. SHapley Additive exPlanations (SHAP) were used for interpretability. RESULTS: Eight key variables (age, urinary albumin (Ualb), total cholesterol (TC), lipid accumulation product (LAP), urinary creatinine, white blood cell count, uric acid and Visceral Adiposity Index) were identified and used for model construction. Among nine algorithms, the Light Gradient Boosting Machine (LightGBM) model showed superior predictive performance. SHAP analysis revealed that Ualb, age, TC and LAP were the most influential predictors. CONCLUSION: Our ML-based model effectively identifies individuals with MASLD at high risk for developing DM. The LightGBM algorithm outperformed other models in both accuracy and interpretability. Key predictors such as Ualb and LAP highlight the importance of renal and metabolic markers in early diabetes risk prediction, offering a new approach for individualised intervention and clinical decision-making.

Fields of Study & Subjects

Liver Disease Diagnosis and Treatment Artificial Intelligence in Healthcare Gout Hyperuricemia Uric Acid

Publication details

Journal / source
BMJ Open
Publisher
BMJ
Volume
16
Issue
1
Pages
e107239–e107239
Publication date
1 January 2026
Language
EN